Payer perspectives on cell and gene therapies: opportunities and challenges
In this on-demand webinar, Professor Stephen Palmer from the University of York discusses his work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.
Fill in your details to watch this webinar
- Value-based pricing is expected by everyone, but which indications have the head-room to allow for higher-cost technologies?
- How does the value of a CAR-T vary between indications? Will we see price erosion as more products come to market?
- How do manufacturers need to think about treatment sequencing and combinations during development?
Duration: 45 minutes. Available to watch on demand.
Ideal viewing: This on-demand webinar is essential viewing for all global, regional, and affiliate market access and HEOR teams involved in the development and commercialization of cell and gene therapies. Please share this with your colleagues.